NEXGEL, Inc. NXGL NASDAQ · Healthcare · United States
$3.88 +2.37% +$0.09
Summary
41 / 100 · Bulios Score
What speaks for it
- Revenue grew by 77% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- It passes only 1 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 76% a year over 5 years. Over the last 3 years it grew by 77% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $6.19M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Contract Manufacturing 89%
- Other Incomes 11%
By region
The company reports no revenue by region.
Contract Manufacturing brings in 89% of revenue.
Segments in detail